23AndMe To Go Public At $3.5Bn With Sir Richard Branson-Backed SPAC
23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.
You may also be interested in...
Theator plans to expand its AI-powered surgical technology platform beyond general surgery and gain a foothold in the US.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
A day after 23andMe gained US FDA go-ahead for a DTC genetic test service to inform patients about their ability to metabolize medications, the agency issued a safety communication, paired with a joint statement from device- and drug-center heads, warning consumers against trusting genetic tests that have not been vetted by FDA.